Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT06380751 as recruiting, last updated 2026-09-02. Enrolment is 788 planned participants, an estimate. Interventions: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane. Primary measures include Progression-Free Survival (Arm 1 vs arm 2). No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Camizestrant, Palbociclib, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Camizestrant, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Camizestrant, Ribociclib, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Saruparib, PARP, AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/